Theravance Biopharma
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Theravance Biopharma's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12% to $57,424,000. The net income raised on -$55,193,000 and profit margin reached -96%. Total operating expenses were $113,459,000.
Profit Margin
| 2014 | 11.68M | -237.03M | -2028.05% |
|---|---|---|---|
| 2015 | 42.12M | -182.21M | -432.56% |
| 2016 | 48.64M | -190.66M | -391.94% |
| 2017 | 15.38M | -285.40M | -1854.97% |
| 2018 | 60.37M | -215.52M | -357.01% |
| 2019 | 73.41M | -236.45M | -322.08% |
| 2020 | 71.85M | -278.01M | -386.9% |
| 2021 | 55.31M | -199.42M | -360.55% |
| 2022 | 51.34M | -92.82M | -180.78% |
| 2023 | 57.42M | -55.19M | -96.11% |
TBPH Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 57.42M | 51.34M | 55.31M | 71.85M | 73.41M | 60.37M | 15.38M | 48.64M | 42.12M | 11.68M |
Cost of revenue | 40.62M | 6.58M | 7.28M | 260.95M | 219.24M | 715K | 6.03M | 2.89M | 4.65M | 4.05M |
Gross profit | 16.80M | 44.75M | 48.02M | -189.09M | -145.83M | 59.65M | 9.35M | 45.75M | 37.46M | 7.63M |
Operating exp. | ||||||||||
Research and development | 40.62M | 63.39M | 193.65M | 260.95M | 219.24M | 201.34M | 173.88M | 141.71M | 129.16M | 168.52M |
Selling and marketing | 5.1M | 8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 113.45M | 130.46M | 292.95M | 369.61M | 325.32M | 298.40M | 269.47M | 226.22M | 219.36M | 240.16M |
Operating income | -56.03M | -91.95M | -257.78M | -297.75M | -251.91M | -238.75M | -260.12M | -180.46M | -181.89M | -232.53M |
Other income (expenses), net | 6.76M | -858K | 58.20M | 11.22M | 10.23M | 11.18M | -11.58M | -92K | 631K | 1.86M |
Income before tax | -49.26M | -92.81M | -199.57M | -286.53M | -241.67M | -226.08M | -271.71M | -180.55M | -181.26M | -230.67M |
Income tax expense | 5.92M | 9K | -151K | -8.52M | -5.22M | -10.56M | 13.69M | 10.11M | 951K | 6.36M |
Net income | -55.19M | -92.82M | -199.42M | -278.01M | -236.45M | -215.52M | -285.40M | -190.66M | -182.21M | -237.03M |
Earnings per share | ||||||||||
Basic EPS | -1 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 |
Diluted EPS | -1 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |